Tcc denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for tcc are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Tcc
## Why Humana Denies Transcranial Current Stimulation (TCC/tCS) as Duplicate Therapy
Humana may issue a duplicate-therapy denial for transcranial current stimulation when it determines that another covered neurological or psychiatric treatment is already in place and that the requested stimulation therapy addresses the same condition through an equivalent mechanism. Common situations include: a patient receiving transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or pharmacotherapy for depression or a neurological condition, where Humana's reviewer asserts that adding transcranial current stimulation provides no additive benefit over the existing regimen.
This denial is appealable when the clinical record demonstrates that the existing treatments are either inadequate, incompletely effective, or target a different aspect of the patient's condition. The treating psychiatrist's or neurologist's documentation of treatment-specific rationale is central to reversing this denial.
## Federal Appeal Rights
Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review followed by independent external review if the internal appeal is denied. The external review window is generally within four months of the final internal denial — confirm the exact deadline from your denial letter. Expedited review is available when delay would seriously jeopardize your health or functioning.
## Appeal Process and Timeline
1. Request the denial rationale in full: Obtain Humana's written explanation identifying which existing therapy it considers duplicative and on what clinical basis. 2. File a Level 1 internal appeal with a targeted letter from your treating clinician explaining the distinct role of transcranial current stimulation in your treatment plan. 3. If denied, file a Level 2 appeal or proceed to external review, which applies independent clinical evidence standards. 4. Request expedited review if your condition involves acute psychiatric or neurological urgency.
## Documentation to Gather
- Diagnosis confirmation: Clinical notes and, where applicable, validated assessment tool scores (submitted as your clinician's documented findings, not as raw numbers to be second-guessed) confirming the diagnosis and current symptom status.
- Prior treatment history with dates and outcomes: A chronological list of all prior and current treatments — medications, TMS, ECT, psychotherapy, or other modalities — with documented response or lack of response to each.
- Clinical rationale for concurrent or sequential use: A detailed letter from your prescribing psychiatrist or neurologist explaining why transcranial current stimulation is not duplicative of the existing treatment, including the specific clinical goal it serves and how it differs mechanistically or functionally from what is already in place.
- Applicable professional society guidance: Your clinician can reference relevant guidelines from the American Psychiatric Association or the applicable specialty society on multimodal or combination approaches for your diagnosis.
## Criteria-Mapping Structure
Obtain Humana's stated criteria for the duplicate-therapy determination — from the denial letter or Humana's published clinical policy. Create a table mapping each criterion against the clinical facts: for each claimed duplicate element, show either that the existing therapy addresses a different target, has been inadequate, or that your clinician has documented a specific non-duplicative rationale. Attach the treating clinician's letter and all relevant clinical notes as labeled exhibits.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →